Neurotech International Limited
On 12 September 2016 (“Prospectus Date”), Neurotech International Limited (ACN 610 205 402) (“Neurotech” or “the Company”) lodged a prospectus (“Prospectus”) with the Australian Securities and Investments Commission (“ASIC”) for the offer of 35,000,000 fully paid ordinary shares in the Company (“Shares”) at an issue price of 20 cents per Share to raise $7,000,000, and the offer of up to 2,529,076 options to acquire Shares to the Lead Manager (as those terms are defined in the Prospectus).
THE OFFER HAS NOW CLOSED, AND THE COMPANY IS NO LONGER ACCEPTING APPLICATIONS FOR SHARES.
An electronic copy of the Prospectus can be obtained in PDF format by clicking below after confirming agreement to the following.
This is an important document that should be read in its entirety. If you do not understand it, you should consult your professional adviser without delay. The paper form of the electronic Prospectus is accessible through this website has been lodged with ASIC.
Applications for securities referred to in the Prospectus must be made in accordance with the terms and conditions set out in the Prospectus. Applications for securities must be made on an application form that accompanies a complete hard copy of the Prospectus. There is no facility for online applications.
The Company will not issue any Shares on the basis of this Prospectus later than 13 months after the Prospectus Date.
The Prospectus does not constitute an offer in any place in which, or to any person to whom, it will not be lawful to make such an offer. No action has been taken to lodge, register or file the Prospectus in any jurisdiction outside Australia. The distribution of this Prospectus outside Australia may be restricted by law and persons who come into possession of this Prospectus outside Australia should seek advice on and observe any such restrictions. The investment described in this Prospectus has not been recommended by any regulatory authority of any jurisdiction including ASIC.
The information on this website is provided for information purposes only and is subject to change without notice. Nothing contained on this website or in the Prospectus constitutes investment, legal, accounting, business, tax or other advice. The information on this website and in the Prospectus does not take into account your investment objectives, financial situation or particular needs. The information on this website does not form part of the Prospectus.
By accessing the Prospectus, you are taken to have confirmed that you have read and understood the notice and agree to these terms and conditions.
Neurotech’s Scientific Advisory Board acts as strategic counsel to Neurotech, guiding company management as it enters the market with its Mente Autism device, in addition to the development of other devices targeting various neurological disorders.
Chaired by Neurotech’s Founder and Chief Scientific Officer Dr Adrian Attard Trevisan, the Scientific Advisory Board will convene once a quarter, and is a key contributor to the Company’s scientific and technological vision.
Prof Paolo Cavallari, MD PhD
Paolo Cavallari is Professor of Human Physiology (2001) at the Medical School of the Università degli Studi in Milan, Italy. Prof Cavallari received his MD (magna cum laude) from the University of Milan in 1982, a Diplome d’Etudes Appofondies in Neurophysiology from the Pierre et Marie Curie University of Paris in 1984, a Doctorat de l'Université from the same university in 1988 and a PhD in Neurological Science from the University of Milan in 1990. He received fellowships from the European Neuroscience Association (1984) and from the IBRO-Wenner-Gren Foundation (1986). He had non-tenure track positions from the INSERM (France, 1985) and the Göteborg University (Sweden, 1987), and tenured as Associate Professor of Human Physiology in 1992 at the Università degli Studi of L'Aquila (1992- 1997), and at Università degli Studi (1997-2001).
Prof Denis Azzopardi, MD PhD
Denis Azzopardi is Professor of Neonatal Medicine at Kings College, London. For many years he has been involved in clinical research in the investigation, assessment and treatment of neonatal encephalopathy, having developed and implemented the first proven therapy to reduce severe brain damage and improve survival after birth asphyxia. In developing this therapy, magnetic resonance spectroscopy was used to demonstrate birth asphyxia in newborn infants leads to delayed brain injury, and that there is a ‘lucid period’ when neuroprotective treatments could potentially be applied. This in turn led to the now standard practice of cooling infants below normal body temperature as the standard practice for those suffering from oxygen deprivation during birth in the United Kingdom (UK). Estimates suggest that this treatment has saved the UK over £100 million in the costs of caring for people affected by birth asphyxia, and is now implemented across the world.
Dr David S Cantor, PhD
Dr David Cantor received his Bachelor’s Degree with Distinction in Psychology from the University of Connecticut. His honours work was in the field of neurophysiological correlates of cross modal integration processes in attention deficit disorders. He received his Masters and Doctorate in psychology at the State University of New York (Stony Brook), where his thesis was focussed on quantitative EEG correlates of autism. He most recently received his Postdoctoral Masters of Science in Psychopharmacology from Fairleigh University.
Dr Cantor is a Fellow with the American College of Forensic Examiners, National Academy of Neuropsychology, and the Academy of Learning and Developmental Disorders. He is also Former President of the EEG and Clinical Neuroscience Society and has also been accepted for special fellowships including Congressional Fellow of the American Psychological Association and the State of New York Intercampus Fellow in the area of brain research.
Dr Anton Grech, MD PhD
Dr Anton Grech graduated as Doctor of Medicine from the University of Malta in 1992. He became a Member of the Royal College of Psychiatrists, UK, in 1997 and a Fellow of the same college in 2011. In 1999 he obtained an M.Sc. in Psychiatry from King’s College, University of London. He trained and worked at the Maudsley Hospital in London, between 1994 and 1998. During 1998 he was also a Clinical-Academic Lecturer in the Department of Psychiatry, Institute of Psychiatry, King’s College, University of London.
Dr Grech returned to Malta in 1999, where he was Senior Registrar in Psychiatry with the National Health Service of Malta until 2003, when he was appointed Consultant Psychiatrist with a special interest in Addictions and Neuropsychiatry. In 2000 he was appointed Lecturer in the Department of Psychiatry of the Faculty of Medicine and Surgery at the University of Malta, and in 2008 he was appointed as Senior Lecturer within the same department. In 2011 he was appointed as Senior Research Fellow in the Bedfordshire Centre for Mental Health Research in association with the University of Cambridge, United Kingdom. In 2011 he was also appointed as Clinical Chairman of the Department of Psychiatry in the Ministry of Health, Malta.
Dr Grech’s work has been published in international psychiatric journals, and he has presented and chaired in various international psychiatric conferences. In 2008 he was chosen as one of the 30 European Scientists to be featured in the book ‘Portraits of Science; Scientists of Tomorrow’, published by the European Federation of Pharmaceutical Industries and Associations, to commemorate its 30th anniversary.